Mumbai: Pfizer said today that its experimental vaccine was more than 90% effective at stopping COVID-19, based on preliminary data from a large study. Pfizer and German partner BioNTech SE are the first drugmakers to show successful data from a large-scale clinical trial of a coronavirus vaccine.
It may be noted that this finding was the result of the first independent analysis of any coronavirus vaccine candidate that is currently in Phase 3 trials. The companies plan to submit data from the full Phase 3 trial for scientific peer-reviewed publications.
Preliminary findings from the Phase 3 trial showed that 94 participants receiving the two-dose vaccine were protected against the virus, 28 days after their first shot.
“Our first set of Phase 3 results, the Kovid-19 vaccine trial, provides preliminary evidence of our vaccine’s ability to inhibit COVID-19,” FFP said in a statement.
UPDATE: We are proud to announce, along with @BioNTech_Group, that our mRNA-based #vaccine candidate has, at an interim analysis, demonstrated initial evidence of efficacy against #COVID19 in participants without prior evidence of SARS-CoV-2 infection.
— Pfizer Inc. (@pfizer) November 9, 2020
Pfizer said it is collecting safety data two months after the last dose, which the FDA requires, to qualify for the EUA, which it expects to be in place by the third week in November.
“We look forward to sharing additional efficacy and safety data generated from thousands of participants in the coming weeks,” Borla said.
The shots made by Pfizer and BioNTech are among 10 possible vaccine candidates in late-stage trials being conducted around the world. Meanwhile, Moderna Inc, another US company has said it hopes to be able to file an application with the FDA later this month. The coronavirus pandemic has so far killed at least 1,255,803 people all over the world.